FEB 27, 2019 1:30 PM PST

Advances in Three-Dimensional Cell Culture in Drug Research and Discovery

Presented at: Drug Discovery 2019
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Vice President and General Manager, Corning Life Sciences
    Biography
      Dr. Richard M. Eglen is Vice President and General Manager of Corning Life Sciences. Dr. Eglen has over 40 years' experience in the Life Sciences industry. Prior to joining Corning in 2011, he was president of Bio-discovery at PerkinElmer and held other executive management positions in the pharmaceutical, diagnostic, and biotech industries. Dr. Eglen has extensive experience in the use of cellular biology to study key drug targets, including GPCRs, kinases, and ion channels. He has also wide experience in assay and instrument technology development for high-throughput screening, imaging, and biomarker detection. He has authored over 350 publications, book chapters, and patents, and serves on numerous industry, academic advisory, and journal editorial boards.

    Abstract

    Cellular research is optimal when using physiologically-relevant cell phenotypes and genotypes of human origin. This assertion has accelerated the adoption of primary cells, stem cells, and increasingly, patient-specific cells in drug discovery. Over the last five years, technological improvements in three-dimensional (3D) cell culture technology, to better mimic in vivo physiology, have also accelerated, not only in the areas of cancer and neurological research, but also in the assessment of clinical candidates for metabolic and toxicological liabilities. In this presentation, existing, and future, developments in 3D cell culture technology, (including the use of phenotypically-relevant human iPS cells) on fundamental research and drug discovery will be addressed. 

    Learning Objectives: 

    1. Understanding current status of 3D technologies  
    2. Understanding applications to disease modeling and drug discovery


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 23, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    Loading Comments...
    Show Resources
    Attendees
    • See more